Signal transduction pathway activity compensates dopamine D 2/D 3 receptor density changes in Parkinson's disease: A preliminary comparative human brain receptor autoradiography study with [ 3H]raclopride and [ 35S]GTPγS

Brain Research

Volumn 1453, Issue , 2012, Pages 56-63

  Farkas, Szabolcs ^a   Nagy, Katalin ^a   Jia, Zhisheng ^b   Hortobágyi, Tibor ^a   Varrone, Andrea ^b   Halldin, Christer ^b   Csiba, László ^a   Gulyás, Balázs ^b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

3H raclopride; Agonist stimulated 35S GTP S binding; autoradiography; Cingulate cortex; Dopamine; Dopamine D 2 D 3 receptor; Frontal cortex; Parkinson's disease; Receptor autoradiography; Striatum

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); RACLOPRIDE;

ARTICLE; AUTORADIOGRAPHY; CAUDATE NUCLEUS; CINGULATE GYRUS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MIDDLE FRONTAL GYRUS; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR DENSITY; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; AUTORADIOGRAPHY; CORPUS STRIATUM; FEMALE; FRONTAL LOBE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); GYRUS CINGULI; HUMANS; MALE; PARKINSON DISEASE; RACLOPRIDE; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SIGNAL TRANSDUCTION;

EID: 84859793567     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2012.03.014     Document Type: Article

References (68)

1. Agid, Y., Javoy-Agid, F., Ruberg, M., 1987. Biochemistry of neurotransmitters in Parkinson's disease. In: Marsden, C.D., Fahn, S. (Eds.), Movement disorders. Butterworth, UK, pp. 166-230.
2. Alexander, G.E., Crutcher, M.D., 1990. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13, 266-271. (Pubitemid 20193456)
3. Alexander, G.E., DeLong, M.R., Strick, P.L., 1986. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 9, 357-381. (Pubitemid 16055790)
4. Alexander, G.M., Schwartzman, R.J., Grothusen, J.R., Brainard, L., Gordon, S.W., 1993. Change in brain dopamine receptor in MPTP parkinsonian monkeys following L-dopa treatment. Brain Res. 625, 276-282. (Pubitemid 23300424)
5. 2-receptors. Neurology 44, 1325-1329.
6. 11C]raclopride. Mov. Disord. 12, 33-38.
7. 2 short receptors and induces receptor sequestration. J. Neural Transm. 104, 867-874.
8. Batchelor, P.E., Liberatore, G.T., Wong, J.Y., Porritt, M.J., Frerichs, F., Donnan, G.A., Howells, D.W., 1999. Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J. Neurosci. 19, 1708-1716. (Pubitemid 29094189)
9. Blanchard, V., Chritin, M., Vyas, S., Savasta, M., Feuerstein, C., Agid, Y., Javoy-Agid, F., Raisman-Vozari, R., 1995. Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J. Neurochem. 64, 1669-1679.
10. 2 agonist (U-91356A) in MPTP-exposed monkeys. J. Pharmacol. Exp. Ther. 272, 854-859.
11. Borbely, K., Brooks, R.A., Wong, D.F., Burns, R.S., Cumming, P., Gjedde, A., 1999. NMSP binding to dopamine and serotonin receptors in MPTP-induced parkinsonism: relation to dopa therapy. Acta Neurol. Scand. 100, 42-52. (Pubitemid 29292550)
12. 2 dopamine receptor stimulation in unilateral 6-hydroxydopamine-lesioned rats. J. Neurosci. 20, 1849-1857.
13. Cai, G., Wang, H.Y., Friedman, E., 2002. Increased dopamine receptor signaling and dopamine receptor-G protein coupling in denervated striatum. J. Pharmacol. Exp. Ther. 302, 1105-1112. (Pubitemid 34920232)
14. Carta, M., Carlsson, T., Kirik, D., Björklund, A., 2007. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130, 1819-1833. (Pubitemid 47343795)
15. 2-like receptor occupancy by dopamine in the putamen of hemiparkinsonian Monkeys. Neuropsychopharmacology 33, 270-278.
16. 1 dopamine receptor mRNA and mu and delta opioid receptors in rat striatum. Neurochem. Int. 25, 355-366.
17. Cheng, H.W., Tong, J., McNeill, T.H., 1998. Lesion-induced axon sprouting in the deafferented striatum of adult rat. Neurosci. Lett. 242, 69-72. (Pubitemid 28082995)
18. de la Fuente-Fernandez, R., Schulzer, M., Mak, E., Calne, D.B., Stoessl, A.J., 2004. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain 127, 888-899. (Pubitemid 38478533)
19. de Lau, L.M., Breteler, M.M., 2006. Epidemiology of Parkinson's disease. Lancet Neurol. 5, 525-535. (Pubitemid 44262284)
20. Dunnett, S.B., Bjorklund, A., 1999. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399, A32-A39.
21. 2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal mesencephalon: an autoradiographic study. Brain Res. 795, 55-62.
22. Féger, J., 1997. Updating the functional model of the basal ganglia. Trends Neurosci. 20, 152-153. (Pubitemid 27116285)
23. 1receptor super sensitivity. II. Unilateral intra-carotid infusion of MPTP in the monkey (Macaca fascicularis). Brain Res. 514, 103-110.
24. 2 receptors in the monkey brain in MPTP-induced parkinsonism. Brain Res. 620, 290-303.
25. Grahn, J.A., Parkinson, J.A., Owen, A.M., 2008. The cognitive functions of the caudate nucleus. Prog. Neurobiol. 86, 141-155.
26. 2-like receptor agonist, produces a sustained antiparkinsonian effect with transient dyskinesias in parkinsonian drug-naive primates. Brain Res. 735, 298-306.
27. Guttman, M., 1992. Dopamine receptors in Parkinson's disease. Ann. Neurol. 31, 184-192.
28. Hall, H., Sedvall, G., Magnusson, O., Kopp, J., Halldin, C., Farde, L., 1994. Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11, 245-256. (Pubitemid 24372813)
29. 3H]PD. Psychopharmacology 128, 240-247.
30. Hall, H., Halldin, C., Farde, L., Sedvall, G., 1998. Whole hemisphere autoradiography of the postmortem human brain. Nucl. Med. Biol. 25, 715-719. (Pubitemid 28557093)
31. Hall, H., Farde, L., Halldin, C., Lundkvist, C., Sedvall, G., 2000. Autoradiographic localization of 5-HT(2A) receptors in the human brain using [(3)H]M100907 and [(11)C]M100907. Synapse 38, 421-431.
32. Hefti, F., Melamed, E., Wurtman, R.J., 1980. Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res. 195, 123-137. (Pubitemid 10077835)
33. Hornykiewicz, O., 1993. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Adv. Neurol. 60, 140-147.
34. 3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment. Brain Res. 709, 259-264.
35. 3 receptors in early and advanced Parkinson's disease. Neurology 54, 1482-1487.
36. Kassiou, M., Banati, R., Holsinger, R.M., Meikle, S., 2009. Challenges in molecular imaging of Parkinson's disease: a brief overview. Brain Res. Bull. 78, 105-108.
37. 125I]epidepride. Brain Res. 609, 237-243.
38. Kish, S.J., Shannak, K., Hornykiewicz, O., 1988. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876-880. (Pubitemid 18090271)
39. Kövari, E., Horvath, J., Bouras, C., 2009. Neuropathology of Lewy body disorders. Brain Res. Bull. 80, 203-210.
40. 3receptor mRNA and binding sites in human brain. Brain Res. Mol. Brain Res. 18, 187-192.
41. Lastres-Becker, I., Cebeira, M., de Ceballos, M., Zeng, B.-Y., Jenner, P., Ramos, J.A., Fernández-Ruiz, J.J., 2001. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's disease and MPTP-treated marmosets. Eur. J. Neurosci. 14, 1827-1832. (Pubitemid 35463701)
42. Lee, T., Seeman, P., Rajput, A., Farley, I.J., Hornykiewicz, O., 1978. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 273, 59-61. (Pubitemid 8312147)
43. Lee, J., Zhu, W.M., Stanic, D., 2008. Sprouting of dopamine terminals and altered dopamine release and uptake in Parkinsonian dyskinaesia. Brain 131, 1574-1587. (Pubitemid 351806467)
44. 2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET. Clin. Neuropharmacol. 22, 277-280.
45. Lopez, A., Muñoz, A., Guerra, M.J., Labandeira-Garcia, J.L., 2001. Mechanisms of the effects of exogenous levodopa on the dopamine-denervated striatum. Neuroscience 103, 639-651. (Pubitemid 32239332)
46. Malmberg, A., Jackson, D.M., Eriksson, A., Mohell, N., 1993. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol. Pharmacol. 43, 749-754. (Pubitemid 23146274)
47. 3 receptors in rat brain: a quantitative autoradiographic study. Neurochem. Int. 56, 747-752.
48. 2receptors to mesostriatal regions of human forebrain. Proc. Natl. Acad. Sci. U S A 91, 11271-11275.
49. Oiwa, Y., Eberling, J.L., Nagy, D., Pivirotto, P., Emborg, M.E., Bankiewicz, K.S., 2003. Overlesioned hemiparkinsonian non-human primate model: correlation between clinical, neurochemical and histochemical changes. Front. Biosci. 8, 155-166.
50. Owen, A.M., 2004. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 10, 525-537. (Pubitemid 39546395)
51. 3 receptor binding or dopamine. Neuroscience 90, 433-445.
52. Playford, E.D., Brooks, D.J., 1992. In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovasc. Brain Metab. Rev. 4, 144-171.
53. 3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome. J. Neurol. Sci. 43, 429-437.
54. Reches, A., Wagner, H.R., Jackson-Lewis, V., Yablonskaya-Alter, E., Fahn, S., 1984. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum. Neurology 34, 1208-1212. (Pubitemid 14068595)
55. Reisine, T.D., Fields, J.Z., Yamamura, H.I., 1977. Neurotransmitter receptor alterations in Parkinson's disease. Life Sci. 21, 335-343. (Pubitemid 8191970)
56. Rinne, U., Rinne, J.O., Rinne, J.K., 1983. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. J. Neural. Transm. Suppl. 18, 279-286.
57. 11C] raclopride. J. Neurol. Sci. 132, 156-161.
58. Robinson, S.W., Caron, M.G., 1997. Selective inhibition of adenylyl cyclase type V by the dopamine D3 receptor. Mol. Pharmacol. 52, 508-514. (Pubitemid 27412977)
59. Seeman, P., Weinshenker, D., Quirion, R., Srivastava, L.K., Bhardwaj, S.K., Grandy, D.K., 2005. Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis. Proc. Natl. Acad. Sci. U S A 102, 3513-3518. (Pubitemid 40328076)
60. 11C] raclopride. Synapse 59, 260-269.
61. Skirboll, S., Wang, J., Mefford, I., Hsiao, J., Bankiewicz, K.S., 1990. In vivo changes of catecholamines in hemiparkinsonian monkeys measured by microdialysis. Exp. Neurol. 110, 187-193.
62. Sossi, V., Dinelle, K., Topping, G.J., Holden, J.E., Doudet, D., Schulzer, M., Ruth, T.J., Stoessl, A.J., de la Fuente-Fernandez, R., 2009. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J. Neurochem. 109, 85-92.
63. 35S]GTPgammaS binding in the human brain. Eur. J. Neurosci. 22, 65-71.
64. Thanvi, B.R., Lo, T.C.N., 2004. Long term motor complications of levodopa: clinical features, mechanisms, and management strategies. Postgrad. Med. J. 80, 452-458. (Pubitemid 39108037)
65. Thanvi, B.R., Munshi, S.K., Vijaykumar, N., Lo, T.C.N., 2003. Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad. Med. J. 79, 561-565. (Pubitemid 37445249)
66. Thobois, S., Vingerhoets, F., Fraix, V., Xie-Brustolin, J., Mollion, H., Costes, N., Mertens, P., Benabid, A.L., Pollak, P., Broussolle, E., 2004. Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study. Arch. Neurol. 61, 1705-1709. (Pubitemid 39463429)
67. Troiano, A., de la Fuente-Fernandez, R., Sossi, V., Schulzer, M., Ruth, T.J., Stoessl, A.J., 2009. Positron emission tomography demonstrates reduced dopamine transporter expression in PD patients with dyskinesias. Neurology 72, 1211-1216.
68. 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov. Disord. 13, 435-443.